{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Table 5:', 'Clinical Laboratory Evaluations', 'Chemistry', 'Coagulation', 'Albumin', 'Prothrombin time (PT) and international normalized', 'Alkaline phosphatase (ALP)', 'ratio (INR)', 'Alanine aminotransferase (ALT)', 'Activated partial thromboplastin time (aPTT)', 'Aspartate aminotransferase (AST)', 'Bilirubin (total and direct)', 'Blood glucose', 'Pregnancy Test', 'Blood urea nitrogen (BUN)', 'Serum (screening) and urine (other scheduled visits)', 'Electrolytes (calcium, sodium, potassium,', '\u00df-hCG for women of childbearing potential (including', 'chloride, phosphorus)', 'adolescents) only', 'Lipid panel (total cholesterol, triglycerides)', 'Creatine kinase', 'Drug screen', 'Creatinine and calculated CLCR', 'Amphetamines', 'Gamma-glutamyltransferase (GGT)', 'Barbiturates', 'Lactate dehydrogenase (LDH)', 'Benzodiazepines', 'Total serum protein', 'Cocaine', 'Uric acid', 'Opiates', 'Amylase', 'Methamphetamine', 'If amylase is > 2 X ULN, reflex to lipase', 'Ecstasy', 'Urinalysis', 'Specific gravity', 'Blood', 'Bilirubin', 'Glucose', 'Additional Tests', 'Leukocytes', 'FSH for women postmenopausal < 2 years', 'Ketones', 'Hepatitis B surface antigen, hepatitis C antibody,', 'Nitrites', 'HIV antibody; if HCV antibody positive, reflex to', 'pH', 'HCV RNA testing', 'Protein', 'Troponin I', 'Urobilinogen', 'Troponin T', 'Microalbumin to creatinine ratio', 'Neutrophil gelatinase-associated lipocalin (NGAL)', 'Reflex microscopy if dipstick is abnormal', 'CK-MB', 'C3', 'Hematology', 'HLA typing', 'Hemoglobin', 'Sample for possible exploratory pharmacogenomic', 'Hematocrit', 'analysis (optional)', 'Erythrocytes', 'C1-INH functional level', 'Mean corpuscular hemoglobin (MCH)', 'C1-INH antigenic level', 'Mean corpuscular hemoglobin concentration', 'C4', '(MCHC)', 'If FGGT, AST, or ALT is > 3 X ULN, reflex to', 'Mean corpuscular volume (MCV)', 'carbohydrate deficient transferrin (CDT)', 'White blood cell count, with differential', 'If GGT, AST, or ALT is > 3 X ULN, reflex to urinary', '(lymphocytes, monocytes, neutrophils,', 'ethyl glucuronide', 'eosinophils, and basophils)', 'Platelets', 'CLCR will be calculated using the Cockcroft-Gault formula and absolute body weight (ABW):', 'CLCR (mL/min) = (140 - age in years) X ABW (kg) (x 0.85 for females)', '72 X serum creatinine (in mg/dL)', '75']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', '11.2.7.', 'Screening for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C', 'Serology', 'Blood samples will be collected at screening for serologic testing for evidence of HIV, chronic', 'hepatitis B, and chronic hepatitis C infection.', '11.2.8.', 'HLA Typing', 'All subjects will have a blood sample drawn at baseline (or any other time point on study if not', 'obtained at baseline) for HLA typing. Samples will be sent to a central laboratory for analysis.', 'The results will not be communicated back to the investigator or subjects because the results are', 'not intended for diagnostic or prognostic purposes and will be used in a research-related fashion', 'only. Relationships between safety assessment findings and HLA typing results may be', 'examined on a meta-study basis.', '11.2.9.', 'Pregnancy Testing', 'FSH will be measured at screening in women declaring themselves postmenopausal < 2 years to', 'establish childbearing status. At screening, a serum pregnancy test should also be drawn in the', 'event a woman subject postmenopausal <2 years is found to be of childbearing potential.', 'For all women and adolescents of childbearing potential, a serum pregnancy test will be', 'administered at screening. This will be done regardless of contraceptive or lifestyle choice', '(ie, those choosing not to engage in heterosexual activity or exclusively having female partners).', 'Urine pregnancy tests will be assessed at all subsequent visits. A serum pregnancy test should', 'immediately be drawn and sent for analysis for any positive urine pregnancy test.', 'Urine pregnancy tests will be provided by the central laboratory but will be resulted locally.', '11.2.10. HAE Diagnostic Confirmation', 'C1-INH functional level and C4 are to be drawn at the screening visit; it is recommended that', 'samples not be drawn within 3 days of C1-INH administration (as used for treatment of an', 'angioedema event). Last use of C1-INH for treatment of an angioedema event prior to this', 'measurement should be denoted in the eCRF.', 'If a subject has a normal C4 level (as is the case in a small percentage of subjects with HAE)', 'drawn at the screening visit, the site may take another C4 level during an angioedema event.', 'A normal C4 level drawn during an angioedema event excludes the subject from study', 'participation.', 'Alternatively, the site may also utilize SERPING-1 gene mutational analysis or a family history', 'of C1-INH deficiency in the case of a normal C4 level. To utilize a family history of C1-INH', 'deficiency to establish an HAE diagnosis for eligibility, the investigator should document this as', \"a source file note based on either the investigator's personal knowledge (ie, if a relative of the\", 'screening subject is also a patient of the same investigator/practice) or interaction with medical', 'staff of the treatment facility where the relative receives HAE care, who confirms the diagnosis.', 'No historical laboratory documentation on the relative should be collected in the source', 'documents. A SERPING-1 mutation known or likely to be associated with HAE Type 1 or 2', 'HAE is acceptable to confirm the diagnosis of HAE. A SERPING-1 analysis that does not', '76']\n\n###\n\n", "completion": "END"}